Twist Bioscience (NASDAQ:TWST) CEO Sells $619,184.20 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 4,573 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $619,184.20. Following the sale, the chief executive officer owned 558,187 shares of the company’s stock, valued at approximately $75,578,519.80. This represents a 0.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $120.79 on Friday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $219.71. The stock’s 50 day moving average is $151.35 and its 200-day moving average is $91.08. The firm has a market capitalization of $7.57 billion, a price-to-earnings ratio of -54.41 and a beta of 2.25.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of the stock. Root Financial Partners LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter worth $33,000. Signaturefd LLC lifted its position in shares of Twist Bioscience by 94.3% during the third quarter. Signaturefd LLC now owns 548 shares of the company’s stock valued at $106,000 after purchasing an additional 266 shares in the last quarter. Allworth Financial LP bought a new position in shares of Twist Bioscience during the second quarter valued at about $62,000. Trifecta Capital Advisors LLC purchased a new position in Twist Bioscience during the second quarter worth about $63,000. Finally, Western Wealth Management LLC purchased a new position in Twist Bioscience during the first quarter worth about $31,000.

Wall Street Analyst Weigh In

Several research firms have weighed in on TWST. UBS Group initiated coverage on shares of Twist Bioscience in a report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective on the stock. TD Cowen lifted their price objective on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Leerink Partners boosted their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Robert W. Baird upped their target price on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Finally, BWS Financial reaffirmed a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $153.00.

Key Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.